The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking. The Food and Drug Administration approved it for patients with mild or early-stage disease. The drug is designed to target and clear away a sticky protein called beta-amyloid. . . .
Read more at www.wishtv.com
